Table 1 Patients’ characteristics and previous therapies.
All (N = 121) | Romiplostim (N = 54) | Eltrombopag (N = 67) | P | |
|---|---|---|---|---|
Gender (% Female) | 58.7 | 59.3 | 58.2 | 0.907 |
Platelets at diagnosis (median, range) | 11.5, 0–95 | 12, 1–82 | 11, 0–95 | 0.899 |
Age (median, range) | 63, 19–96 | 57, 19–90 | 66, 21–96 | 0.115 |
Hypertension (%) | 28.1 | 16.7 | 37.3 | 0.012 |
Diabetes (%) | 14.0 | 11.1 | 16.4 | 0.404 |
Liver disease (%) | 4.1 | 3.7 | 4.5 | 0.832 |
Previous neoplasia (%) | 6.6 | 5.5 | 8.1 | 0.675 |
Previous vascular event (%) | 9.1 | 7.4 | 7.2 | 0.563 |
Chronic phase (%) | 67.8 | 68.5 | 67.2 | 0.874 |
Patients that started TPO-RA in the first 18 months (January 2012–June 2013) (%) | 48.8 | 53.7 | 44.8 | 0.329 |
Previous therapies | ||||
1st line Prednisone (%) • Responders (%) | 85.9 65.4 | 90.7 69.4 | 82.1 61.8 | 0.173 0.335 |
Dexamethasone (%) • Responders (%) | 29.7 61.1 | 33.3 55.5 | 26.9 66.7 | 0.439 0.494 |
Rituximab (%) • Responders (%) | 19.0 56.5 | 25.9 71.4 | 13.4 33.3 | 0.082 0.072 |
Splenectomy (%) • Responders (%) | 17.1 62.9 | 18 61.1 | 17 64.7 | 0.337 0.826 |
IVIG (%) • Responders (%) | 57.8 78.6 | 59.3 81.2 | 56.7 76.3 | 0.778 0.616 |
Immunosuppressants (%) • Responders (%) | 13.2 31.2 | 13.0 28.6 | 13.4 33.3 | 0.979 0.838 |
Danazol (%) • Responders (%) | 10.7 46.1 | 13.0 42.9 | 8.9 50.0 | 0.479 0.797 |
